These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 10507279

  • 1. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia.
    Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK.
    J Clin Psychiatry; 1999; 60 Suppl 19():38-45; discussion 46. PubMed ID: 10507279
    [Abstract] [Full Text] [Related]

  • 2. [Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France].
    Le Pen C, Lilliu H, Allicar MP, Olivier V, Gregor KJ.
    Encephale; 1999; 25(4):281-6. PubMed ID: 10546082
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V, Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine.
    JAMA; 2003 Nov 26; 290(20):2693-702. PubMed ID: 14645311
    [Abstract] [Full Text] [Related]

  • 4. Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.
    Tunis SL, Croghan TW, Heilman DK, Johnstone BM, Obenchain RL.
    Med Care; 1999 Jul 26; 37(7):678-91. PubMed ID: 10424639
    [Abstract] [Full Text] [Related]

  • 5. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
    Glazer WM, Johnstone BM.
    J Clin Psychiatry; 1997 Jul 26; 58 Suppl 10():50-4. PubMed ID: 9265917
    [Abstract] [Full Text] [Related]

  • 6. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
    Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G.
    Pharmacoeconomics; 1999 May 26; 15(5):469-80. PubMed ID: 10537964
    [Abstract] [Full Text] [Related]

  • 7. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE.
    Am J Manag Care; 1998 Mar 26; 4(3):345-55. PubMed ID: 10178497
    [Abstract] [Full Text] [Related]

  • 8. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH, Goa KL.
    Pharmacoeconomics; 1999 Jun 26; 15(6):611-40. PubMed ID: 10538333
    [Abstract] [Full Text] [Related]

  • 9. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.
    Palmer CS, Brunner E, Ruíz-Flores LG, Paez-Agraz F, Revicki DA.
    Arch Med Res; 2002 Jun 26; 33(6):572-80. PubMed ID: 12505105
    [Abstract] [Full Text] [Related]

  • 10. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME.
    Am J Psychiatry; 1997 Apr 26; 154(4):457-65. PubMed ID: 9090331
    [Abstract] [Full Text] [Related]

  • 11. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.
    Hamilton SH, Edgell ET, Revicki DA, Breier A.
    Int Clin Psychopharmacol; 2000 Sep 26; 15(5):245-55. PubMed ID: 10993126
    [Abstract] [Full Text] [Related]

  • 12. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
    Gomez JC, Crawford AM.
    J Clin Psychiatry; 2001 Sep 26; 62 Suppl 2():6-11. PubMed ID: 11232753
    [Abstract] [Full Text] [Related]

  • 13. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
    Kinon BJ, Roychowdhury SM, Milton DR, Hill AL.
    J Clin Psychiatry; 2001 Sep 26; 62 Suppl 2():17-21. PubMed ID: 11232746
    [Abstract] [Full Text] [Related]

  • 14. [Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain].
    Sacristán JA, Gómez JC, Salvador-Carulla L.
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997 Sep 26; 25(4):225-34. PubMed ID: 9412161
    [Abstract] [Full Text] [Related]

  • 15. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ.
    BMC Psychiatry; 2005 Jan 13; 5():3. PubMed ID: 15649317
    [Abstract] [Full Text] [Related]

  • 16. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
    Almond S, O'Donnell O.
    Pharmacoeconomics; 2000 Apr 13; 17(4):383-9. PubMed ID: 10947493
    [Abstract] [Full Text] [Related]

  • 17. The impact of schizophrenic patient functionality on service utilization and cost. Based on a presentation by Sandra L. Tunis, PhD.
    Am J Manag Care; 1999 Jul 13; 5(10 Suppl):S583-90. PubMed ID: 10539493
    [Abstract] [Full Text] [Related]

  • 18. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
    Tollefson GD, Sanger TM, Lu Y, Thieme ME.
    Arch Gen Psychiatry; 1998 Mar 13; 55(3):250-8. PubMed ID: 9510219
    [Abstract] [Full Text] [Related]

  • 19. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
    Hamilton SH, Revicki DA, Genduso LA, Beasley CM.
    Neuropsychopharmacology; 1998 Jan 13; 18(1):41-9. PubMed ID: 9408917
    [Abstract] [Full Text] [Related]

  • 20. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
    Ishigooka J, Inada T, Miura S.
    Psychiatry Clin Neurosci; 2001 Aug 13; 55(4):403-14. PubMed ID: 11442893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.